Abstract:e13603 Background: Oncology therapeutic development has high failure rates with substantial costs. Advances in technology, including molecular characterisations of cancer and computational power, provide the opportunity to better model therapeutic response for existing and emerging therapies. Methods: Concr adapted Bayesian statistical principles used by astrophysicists to effectively integrate multi-dimensional data (genomic & transcriptomic) for accurate modelling of cancer biology. Our proprietary computational framework was applied to predict clinical response and survival through construction of digital twins and in silico simulations of clinical trials. Predicted log odds ratios (LOR) were generated for drug response and compared to published data from 8 suitable historical clinical trials. Three distinct models underpin this framework: Drug Efficacy, Treatment Response & Overall Survival (OS). Three publicly available datasets were used for training: Cancer Therapeutic Response Portal ( in vitro dose-response data), Cancer Cell Line Encyclopaedia and TCGA. Results: For all 8 clinical studies, the digital twin model accurately simulated both trial arms, compared drug efficacy across arms and predicted which treatment was most active. Unblinded evaluation: Our model accurately predicted gemcitabine would have greater clinical benefit than 5-FU (LOR -0.10, P <0.0001) in metastatic pancreatic cancer. In advanced breast cancer, the model predicted docetaxel had a higher response rate than doxorubicin, and carboplatin response rates were similar to docetaxel in BRCA wild-type patients. In platinum-sensitive recurrent ovarian cancer, the model predicted cisplatin-based combination had a higher response rate than paclitaxel. Blinded evaluation: Using data for paclitaxel, the model correctly predicted that nab-paclitaxel+gemcitabine response rates were higher than gemcitabine in metastatic pancreatic cancer (predicted LOR -0.090, p = CMF, adjuvant TC > AC and adjuvant tamoxifen was superior to capecitabine. The underlying pan-tumour Overall Survival model used a Random Survival Forest approach, trained on 23 cancers with predictive accuracy of 0.78 AUC ROC and C-index 0.71. To enable cohort enrichment for drug response, the model segmented patient cohorts into treatment responder and non-responder. Using this approach, the log odds increased for drug response rate for 16 of the 19 different cancers and 14 of the different 17 drugs. Conclusions: Our digital twin model represents transformative technology for clinical trial simulation with strong potential for accelerating and de-risking clinical drug development, and utility for synthetic control arms.

Clinical Success of Drug Targets Prospectively Predicted by in Silico Study

Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients?

Learning the Drug Target-Likeness of A Protein

Can an in Silico Drug‐Target Search Method Be Used to Probe Potential Mechanism of Medicinal Plant Ingredients?

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

In silico prediction of novel therapeutic targets using gene–disease association data

Clinical Advancement Forecasting

In Silico Methods for Identification of Potential Active Sites of Therapeutic Targets

Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.

In-Silico Approaches to Multi-target Drug Discovery

Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning

Prediction of clinical trials outcomes based on target choice and clinical trial design with multi‐modal artificial intelligence

In-silico Target Prediction by Ensemble Chemogenomic Model Based on Multi-Scale Information of Chemical Structures and Protein Sequences.

Machine learning prediction of oncology drug targets based on protein and network properties

Computer-Aided Drug Target Search

Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic

Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.

Prediction of Potential Drug Targets Based on Simple Sequence Properties

What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets

Construction of Enriched Resource for Primary Therapeutic Targets of Approved and Clinical Trial Drugs

Dynamic Clinical Success Rates for Drugs in the 21st Century